▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Novo Nordisk (NYSE: NVO)

$54.40

(-3.0%)

-$1.68

Price as of October 17, 2025, 3:58 p.m. ET

Novo Nordisk Return vs. S&P

	1 Year	5 Year	5 Year Annualized	Since IPO
NVO	-52.71%	+66.75%	+10.76%	+47,574%
S&P	+14.08%	+91.29%	+13.83%	+5,054%

Novo Nordisk Company Info

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

News & Analysis

The Fool has written over 600 articles on Novo Nordisk.

Featured Article

How GoodRx Makes Money

Rachel Warren | Oct 18, 2025

Featured Article

Meet the 1.4% Yield Dividend Stock That Could Soar in 2026

The company is one of two major players in the rapidly growing obesity drug market. Yet, the stock has lost half its value.

Justin Pope | Oct 15, 2025

The Smartest Growth Stock to Buy With $100 Right Now

Prosper Junior Bakiny | Oct 13, 2025

This beaten-down drugmaker is well positioned to turn things around.

3 Top Healthcare Stocks to Buy in October

Justin Pope | Oct 13, 2025

Healthcare stocks haven't been very popular this year. It could be a great time to buy some of the industry's leaders.

Should You Buy Novo Nordisk Right Now?

Lee Samaha | Oct 12, 2025

The fallen pharma giant could make a big comeback in 2026.

The Largest Healthcare Companies by Market Cap in October 2025

Lyle Daly | Oct 9, 2025

Eli Lilly, Johnson & Johnson, and AbbVie command the healthcare sector.

Eastover Opens a Brand New $3.3 Million Novo Nordisk Position

Josh Kohn-Lindquist | Oct 9, 2025

Carolina Wealth Makes a Big $6 Million Bet on Novo Nordisk (NYSE: NVO)

Josh Kohn-Lindquist | Oct 8, 2025

Valuation

Podcast Episodes

Diabetes Deep-Dive: What Investors Need to Know About This Devastating Disease

Explaining diabetes, its various treatment options, and what the future may have in store for this disease.

Todd Campbell and Gaby Lapera | Jun 18, 2016

Earnings Transcripts

Novo Nordisk (NVO) Q4 2024 Earnings Call Transcript

NVO earnings call for the period ending December 31, 2024.

Motley Fool Transcribing | Feb 5, 2025

Novo Nordisk (NVO) Q3 2024 Earnings Call Transcript

NVO earnings call for the period ending September 30, 2024.

Motley Fool Transcribing | Nov 6, 2024

Novo Nordisk (NVO) Q2 2024 Earnings Call Transcript

NVO earnings call for the period ending June 30, 2024.

Motley Fool Transcribing | Aug 7, 2024

Novo Nordisk (NVO) Q1 2024 Earnings Call Transcript

NVO earnings call for the period ending March 31, 2024.

Motley Fool Transcribing | May 2, 2024

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services